Germany's Merck suffers setback with cancer drug
German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
Medications
Dec 19, 2012 |
not rated yet |
0
For psychiatric patients, cancer is often spotted too late
(HealthDay)—People with psychiatric disorders have a 30 percent higher death rate from cancer, even though they are no more likely to develop the disease than others. And the underlying reason may be relatively ...
Cancer
Dec 19, 2012 |
not rated yet |
0
Spotting ovarian cancer, before it's too late
(Medical Xpress)—At just 28 percent, the five-year survival rate for women diagnosed with ovarian cancer is much lower than in other cancer cases. And, the disease can easily go unnoticed, making it difficult ...
Cancer
Dec 19, 2012 |
not rated yet |
0
Men's cancer risk to climb to one in two as research drives up survival
A man's lifetime risk of developing cancer is set to reach one in two by 2027 according to new Cancer Research UK figures released today (Wednesday). ...
Cancer
Dec 19, 2012 |
not rated yet |
0
Long-term survival after less-invasive repair of abdominal aneurysm same as with 'open' procedure
Despite earlier signs that a less-invasive surgery is safer and better than "open" operations to repair potentially lethal abdominal aortic aneurysms, a study led by a Johns Hopkins professor shows survival rates after four ...
Surgery
Dec 18, 2012 |
not rated yet |
0
|
Surviving sepsis with LECT2
Failure to launch an adequate immune response may be at the root of septic shock, according to a study published in The Journal of Experimental Medicine on December 17th.
Medical research
Dec 17, 2012 |
not rated yet |
0
Study finds new targets for drugs to defeat aggressive brain tumor
University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy ...
Cancer
Dec 14, 2012 |
not rated yet |
0
|
Thyroid cancer cases double in 20 years, report finds
The number of people diagnosed with thyroid cancer in England has doubled since the early 1990s, according to a new report published by the National Cancer Intelligence Network (NCIN) today (Friday).
Cancer
Dec 14, 2012 |
not rated yet |
0
Olympians live longer than general population... But cyclists no survival advantage over golfers
Olympic medallists live longer than the general population, regardless of country of origin, medal won, or type of sport played, finds a study in the Christmas issue published on BMJ today.
Health
Dec 13, 2012 |
4.3 / 5 (3) |
5
|
MicroRNA-218 targets medulloblastoma, most aggressive childhood brain cancer
Between the blueprint of the genome and the products of its expression lie microRNAs, which can boost or lower the rate at which genes become stuff. In fact, many cancers use microRNA to magnify the expression of faulty genes ...
Cancer
Dec 13, 2012 |
5 / 5 (1) |
0
|
Scientists identify new biomarker for cancer in bone marrow: Promise for patients of multiple myeloma
Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow. Patients with this form of cancer usually do not ...
Cancer
Dec 13, 2012 |
not rated yet |
0
Why is the flu more common during the winter season?
(Medical Xpress)—Influenza, commonly known as the flu, has distinct transmission patterns around the world. In temperate regions, influenza's occurrence peaks during the winter season, while in some tropical regions, the ...
Diseases, Conditions, Syndromes
Dec 13, 2012 |
not rated yet |
0
Bevacizumab doesn't prolong survival in stage II-III colon CA
(HealthDay)—For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival, according ...
Cancer
Dec 12, 2012 |
not rated yet |
0
Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of ...
Cancer
Dec 10, 2012 |
not rated yet |
0
New multiple myeloma drug shows promise in treating people with advanced disease
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount ...
Cancer
Dec 10, 2012 |
5 / 5 (1) |
0
